Eversept Partners, LP Savara Inc Transaction History

Eversept Partners, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$0.71 - $4.91 $224,842 - $1.55 Million	-316,679 Closed	0 $0
Q3 2019 Nov 08, 2023	BUY	$2.16 - $3.2 $160,997 - $238,515	74,536 Added 30.78%	316,679 $839,000
Q3 2019 Nov 13, 2019	BUY	$2.16 - $3.2 $160,997 - $238,515	74,536 Added 30.78%	316,679 $839,000
Q2 2019 Nov 08, 2023	BUY	$2.37 - $11.7 $573,878 - $2.83 Million	242,143 New	242,143 $573,000
Q2 2019 Aug 13, 2019	BUY	$2.37 - $11.7 $573,878 - $2.83 Million	242,143 New	242,143 $574,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.